On December 9, 2020, Reneo Pharmaceuticals announced it has raised $95 million in a Series B financing. The financing was co-led by Novo Ventures and Abingworth, and was supported by existing investors New Enterprise Associates, RiverVest Venture Partners, Pappas Capital, and Lundbeckfonden Ventures, as well as new investors Rock Springs Capital, Aisling Capital, Amzak Health, and other investors. Wilson Sonsini Goodrich & Rosati represented lead investors Novo Ventures and Abingworth in the transaction.

Reneo is a clinical-stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. The company develops REN001, an oral, once-daily investigational drug known to control several genes involved in mitochondrial activity. According to the press release, the financing will allow Reneo to achieve several key clinical milestones, including completion of a global phase 2 study in primary mitochondrial myopathies.

The Wilson Sonsini team advising the lead investors includes partner Dan Koeppen, associate Meghan Burton, and venture counsel Bridget Balisy​.

Please see Reneo's press release for more information.